All In Biotech

Drug Trial Radar · NCT06669533

Use Misoprostol to Optimize Prevention of Cervical Cancer

Misoprostol to Optimizing Prevention of Cancer of the Cervix: A Double-Blind Randomized Controlled Trial

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 840 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

840

Planned (sponsor's estimate)

Start

Feb 25, 2025

Primary completion

Nov 4, 2027

Study completion Nov 11, 2028

Sponsor

Lead sponsor
University of Alabama at BirminghamAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Cameroon Baptist Convention Health; National Cancer Institute (NCI)
First posted
Nov 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Screening
FDA-regulated drug
No
Who can join
Female only, from 25 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a double-blind randomized controlled trial of 420 non-pregnant women undergoing cancer screening by visual inspection with acetic acid (VIA) who have Type 3 transformation zone (TZ) and randomized to receive either Misoprostol or placebo.

Conditions

  • Cervical Cancers

Interventions

  • PlaceboDrug

    Participants will receive placebo (3 tablets) administered vaginally 2-3 hours and 4-6 hours prior to visual inspection with acetic acid (VIA).

  • MisoprostolDrug

    Participants will receive 600 mcg misoprostol (3 tablets) administered vaginally 2-3 hours and 4-6 hours prior to visual inspection with acetic acid (VIA).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Conversion rate from Type 3 transformation zone (TZ) to Types 1 or 2Time frame: Approximately 2-3 hours and approximately 4-6 hours since drug administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cameroon Baptist Convention Health Core, EtougEbe Baptist Hospital Yaoundé

    Yaoundé, Center Region, Cameroon · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.